Portfolio Company · Operating Co.

Crescendo Biologics

a portfolio company of

Status on record: Current

Investment year: 2018

PE Firm Index

Who owns Crescendo Biologics?

Crescendo Biologics is listed as a current portfolio company of Andera Partners on Andera Partners' own portfolio page. Andera Partners has owned Crescendo Biologics since 2018, per Andera Partners' portfolio page.

Company Snapshot

Crescendo Biologics is a Technology platform producing tunable biologics for the treatment of cancer company. Its owner on record, Andera Partners, is a private equity firm. Andera Partners lists 291 companies in the index, 29 of them in Technology platform producing tunable biologics for the treatment of cancer.

SectorTechnology platform producing tunable biologics for the treatment of cancer

Parent PE firmAndera Partners

Ownership statusCurrent

WebsiteNot on record

About the owner

Andera Partners

Strategy: Private Equity, Development Capital, Sponsorless Mezzanine Investment, Co-Invest, Infrastructure Investment
Sectors: Life Sciences, Biotechnologies, Mid-Caps
Companies in the index: 291

Andera Partners is a private equity asset management firm that invests in companies and their management to support growth and innovation.

Read the Andera Partners profile

Questions about Crescendo Biologics

Who owns Crescendo Biologics?

What sector is Crescendo Biologics in?

Crescendo Biologics is in Technology platform producing tunable biologics for the treatment of cancer. Classified from the owner's portfolio label.

What else does Andera Partners own in Technology platform producing tunable biologics for the treatment of cancer?

Andera Partners lists 28 other Technology platform producing tunable biologics for the treatment of cancer companies in the index, including A2IA, ADF, Antemeta, Axonics and CDS Group.

Sources

Andera Partners
https://www.anderapartners.com/en/investment-portfolio/

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Crescendo Biologics and does not provide investment advice.

Other portfolio companies of Andera Partners

6 of 290 shown

“Pôle Fine Art” Horus Finance

Transportation & Logistics

2CGroup

B2B/B2C services

A2IA

Software for document capture and recognition

Abivax

Therapeutic products

Abrisud

Development, production and distribution of swimming pool enclosures

ACB

Printed circuit board manufacturer

See the full Andera Partners portfolio.

Other Technology platform producing tunable biologics for the treatment of cancer companies held by Andera Partners

A2IA ADF Antemeta Axonics CDS Group DP Logiciels

Other Technology platform producing tunable biologics for the treatment of cancer portfolio companies

10bis

via TA Associates

via The Carlyle Group

via Main Capital Partners

2nd Story Software, Inc.

via TA Associates

360Player

via Five Elms Capital

360T Group

via Summit Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Andera Partners

Status: Current

Investment year: 2018

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.